Filing Flows › Comparisons › CUE vs AQST
Cue Biopharma vs Aquestive Therapeutics: CUE and AQST compared
Cue Biopharma is the larger company: $7.9M of revenue in its latest quarter (Q2 2026) against $7.6M for Aquestive Therapeutics (Q3 2026). Cue Biopharma is growing faster (+167% against -41% a year earlier).
Where the money goes: CUE and AQST
Cue Biopharma (CUE) · Q2 2026
Cue Biopharma, Q2 2026: revenue $7.9M (+167% year over year), net loss $153M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
Aquestive Therapeutics (AQST) · Q3 2026
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
| Cue Biopharma (CUE) | Aquestive Therapeutics (AQST) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $7.9M | $7.6M |
| Revenue growth, Y/Y | +167% | -41% |
| Operating margin | n/m | -191.5% |
| Net earnings | −$153M | −$16.5M |
| Net margin | — | -218.3% |
| Operating cash flow | −$29.0M | −$7.0M |
Where the revenue comes from
Aquestive Therapeutics
- Manufacture and supply revenue: $6.7M (88%)
- License and Royalty Revenue: $824K (11%)
- Co-development and research fees: $74K (1%)
Questions
Which is bigger, Cue Biopharma or Aquestive Therapeutics?
Cue Biopharma is the larger company: $7.9M of revenue in its latest quarter (Q2 2026) against $7.6M for Aquestive Therapeutics (Q3 2026).
Is Cue Biopharma or Aquestive Therapeutics growing faster?
Cue Biopharma is growing faster (+167% against -41% a year earlier).
More: Cue Biopharma earnings · how Cue Biopharma makes money · Aquestive Therapeutics earnings · how Aquestive Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.